vs
Apellis Pharmaceuticals, Inc.（APLS）与PRA GROUP INC（PRAA）财务数据对比。点击上方公司名可切换其他公司
PRA GROUP INC的季度营收约是Apellis Pharmaceuticals, Inc.的1.7倍（$333.4M vs $199.9M），PRA GROUP INC净利率更高（17.0% vs -29.5%，领先46.4%），PRA GROUP INC同比增速更快（13.7% vs -5.9%），Apellis Pharmaceuticals, Inc.自由现金流更多（$-14.3M vs $-90.4M），过去两年PRA GROUP INC的营收复合增速更高（14.2% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
PRA Group是一家总部位于美国弗吉尼亚州诺福克的公开上市企业，主营不良债务收购与债务催收业务。公司以折扣价格从信用卡发行机构及其他各类金融机构手中收购个人逾期债务，随后开展催收工作以追回全额欠款。该公司成立于1996年，目前在全球18个国家拥有超过3200名员工。
APLS vs PRAA — 直观对比
营收规模更大
PRAA
是对方的1.7倍
$199.9M
营收增速更快
PRAA
高出19.6%
-5.9%
净利率更高
PRAA
高出46.4%
-29.5%
自由现金流更多
APLS
多$76.1M
$-90.4M
两年增速更快
PRAA
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $333.4M |
| 净利润 | $-59.0M | $56.5M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 37.7% |
| 净利率 | -29.5% | 17.0% |
| 营收同比 | -5.9% | 13.7% |
| 净利润同比 | -62.2% | 206.3% |
| 每股收益（稀释后） | $-0.40 | $1.47 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSPRAA
| Q4 25 | $199.9M | $333.4M | ||
| Q3 25 | $458.6M | $311.1M | ||
| Q2 25 | $178.5M | $287.7M | ||
| Q1 25 | $166.8M | $269.6M | ||
| Q4 24 | $212.5M | $293.2M | ||
| Q3 24 | $196.8M | $281.5M | ||
| Q2 24 | $199.7M | $284.2M | ||
| Q1 24 | $172.3M | $255.6M |
净利润APLSPRAA
| Q4 25 | $-59.0M | $56.5M | ||
| Q3 25 | $215.7M | $-407.7M | ||
| Q2 25 | $-42.2M | $42.4M | ||
| Q1 25 | $-92.2M | $3.7M | ||
| Q4 24 | $-36.4M | $18.5M | ||
| Q3 24 | $-57.4M | $27.2M | ||
| Q2 24 | $-37.7M | $21.5M | ||
| Q1 24 | $-66.4M | $3.5M |
营业利润率APLSPRAA
| Q4 25 | -25.6% | 37.7% | ||
| Q3 25 | 48.7% | -101.4% | ||
| Q2 25 | -18.6% | 29.6% | ||
| Q1 25 | -50.0% | 27.7% | ||
| Q4 24 | -12.3% | 32.1% | ||
| Q3 24 | -24.0% | 32.0% | ||
| Q2 24 | -14.7% | 31.4% | ||
| Q1 24 | -36.0% | 26.0% |
净利率APLSPRAA
| Q4 25 | -29.5% | 17.0% | ||
| Q3 25 | 47.0% | -131.0% | ||
| Q2 25 | -23.6% | 14.7% | ||
| Q1 25 | -55.3% | 1.4% | ||
| Q4 24 | -17.1% | 6.3% | ||
| Q3 24 | -29.2% | 9.6% | ||
| Q2 24 | -18.9% | 7.6% | ||
| Q1 24 | -38.5% | 1.4% |
每股收益（稀释后）APLSPRAA
| Q4 25 | $-0.40 | $1.47 | ||
| Q3 25 | $1.67 | $-10.43 | ||
| Q2 25 | $-0.33 | $1.08 | ||
| Q1 25 | $-0.74 | $0.09 | ||
| Q4 24 | $-0.30 | $0.47 | ||
| Q3 24 | $-0.46 | $0.69 | ||
| Q2 24 | $-0.30 | $0.54 | ||
| Q1 24 | $-0.54 | $0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $104.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $979.9M |
| 总资产 | $1.1B | $5.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSPRAA
| Q4 25 | $466.2M | $104.4M | ||
| Q3 25 | $479.2M | $107.5M | ||
| Q2 25 | $370.0M | $131.6M | ||
| Q1 25 | $358.4M | $128.7M | ||
| Q4 24 | $411.3M | $105.9M | ||
| Q3 24 | $396.9M | $141.1M | ||
| Q2 24 | $360.1M | $118.9M | ||
| Q1 24 | $325.9M | $108.1M |
总债务APLSPRAA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSPRAA
| Q4 25 | $370.1M | $979.9M | ||
| Q3 25 | $401.2M | $928.5M | ||
| Q2 25 | $156.3M | $1.3B | ||
| Q1 25 | $164.2M | $1.2B | ||
| Q4 24 | $228.5M | $1.1B | ||
| Q3 24 | $237.1M | $1.2B | ||
| Q2 24 | $264.3M | $1.1B | ||
| Q1 24 | $266.7M | $1.1B |
总资产APLSPRAA
| Q4 25 | $1.1B | $5.1B | ||
| Q3 25 | $1.1B | $5.0B | ||
| Q2 25 | $821.4M | $5.4B | ||
| Q1 25 | $807.3M | $5.1B | ||
| Q4 24 | $885.1M | $4.9B | ||
| Q3 24 | $901.9M | $4.9B | ||
| Q2 24 | $904.5M | $4.7B | ||
| Q1 24 | $831.9M | $4.5B |
负债/权益比APLSPRAA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $-85.5M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $-90.4M |
| 自由现金流率自由现金流/营收 | -7.1% | -27.1% |
| 资本支出强度资本支出/营收 | 0.1% | 1.4% |
| 现金转化率经营现金流/净利润 | — | -1.51× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $-169.4M |
8季度趋势，按日历期对齐
经营现金流APLSPRAA
| Q4 25 | $-14.2M | $-85.5M | ||
| Q3 25 | $108.5M | $-10.1M | ||
| Q2 25 | $4.4M | $-12.9M | ||
| Q1 25 | $-53.4M | $-52.6M | ||
| Q4 24 | $19.4M | $-94.6M | ||
| Q3 24 | $34.1M | $-35.0M | ||
| Q2 24 | $-8.3M | $-29.5M | ||
| Q1 24 | $-133.0M | $-73.0M |
自由现金流APLSPRAA
| Q4 25 | $-14.3M | $-90.4M | ||
| Q3 25 | $108.3M | $-11.3M | ||
| Q2 25 | $4.4M | $-14.2M | ||
| Q1 25 | $-53.4M | $-53.5M | ||
| Q4 24 | $19.3M | $-98.6M | ||
| Q3 24 | — | $-36.1M | ||
| Q2 24 | $-8.4M | $-30.8M | ||
| Q1 24 | $-133.3M | $-73.5M |
自由现金流率APLSPRAA
| Q4 25 | -7.1% | -27.1% | ||
| Q3 25 | 23.6% | -3.6% | ||
| Q2 25 | 2.5% | -4.9% | ||
| Q1 25 | -32.0% | -19.8% | ||
| Q4 24 | 9.1% | -33.6% | ||
| Q3 24 | — | -12.8% | ||
| Q2 24 | -4.2% | -10.8% | ||
| Q1 24 | -77.3% | -28.8% |
资本支出强度APLSPRAA
| Q4 25 | 0.1% | 1.4% | ||
| Q3 25 | 0.0% | 0.4% | ||
| Q2 25 | 0.0% | 0.4% | ||
| Q1 25 | 0.0% | 0.3% | ||
| Q4 24 | 0.0% | 1.4% | ||
| Q3 24 | 0.0% | 0.4% | ||
| Q2 24 | 0.0% | 0.5% | ||
| Q1 24 | 0.2% | 0.2% |
现金转化率APLSPRAA
| Q4 25 | — | -1.51× | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | -0.30× | ||
| Q1 25 | — | -14.37× | ||
| Q4 24 | — | -5.13× | ||
| Q3 24 | — | -1.29× | ||
| Q2 24 | — | -1.37× | ||
| Q1 24 | — | -21.01× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
PRAA
| GB | $170.1M | 51% |
| Other | $163.3M | 49% |
